A Phase 1 Study of PYX-201 in People With Advanced Solid Tumors

Full Title

A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants with Advanced Solid Tumors

Purpose

Researchers are evaluating PYX-201 in people with solid tumors that have spread and keep growing after treatment. The people in this study have these cancers:

• Head and neck cancer
• Thyroid cancer
• Salivary gland cancer
• Sarcoma chordoma
• Breast cancer

PYX-201 is an antibody-drug conjugate (ADC). ADCs are made up of an antibody linked to a drug. The antibody binds to specific proteins on cancer cells. The linked drug enters these cells and kills them, with a reduced risk of harming other cells.

By destroying these cells, PYX-201 may help slow or stop the growth of your cancer. It is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have one of the cancers listed above, which continues to grow despite treatment.
• Have recovered from the serious side effects of prior therapies before getting PYX-201.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Winston Wong’s office at 646-608-4245.